Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Antigen-specific CAR T Cells for Multiple Myeloma
NCT03271632Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in multiple myeloma (MM), sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Percentage of patients with treatment related adverse effect at 1 month. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03271632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03271632.